miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers-Reference-Cited by-同舟云学术

miR200-regulated CXCL12β promotes fibroblast heterogeneity and immunosuppression in ovarian cancers

Published:2018-03-13 Issue:1 Volume:9 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Givel Anne-Marie,Kieffer Yann,Scholer-Dahirel Alix,Sirven Philemon,Cardon Melissa,Pelon Floriane,Magagna Ilaria,Gentric Géraldine,Costa Ana,Bonneau Claire,Mieulet Virginie,Vincent-Salomon Anne,Mechta-Grigoriou Fatima^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/s41467-018-03348-z.pdf

Reference70 articles.

1. Audeh, M. W. et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376, 245–251 (2010).

2. Fong, P. C. et al. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512–2519 (2010).

3. Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382–1392 (2012).

4. Pujade-Lauraine, E. & Combe, P. Recurrent ovarian cancer. Ann. Oncol. 27(Suppl 1), i63–i65 (2016).

5. Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154–2164 (2016).

Cited by 212 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reprogramming of normal fibroblasts into ovarian cancer-associated fibroblasts via non-vesicular paracrine signaling induces an activated fibroblast phenotype;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2024-10

2. Cancer associated fibroblasts and metabolic reprogramming: unraveling the intricate crosstalk in tumor evolution;Journal of Hematology & Oncology;2024-09-02

3. Spatial mapping of immunosuppressive CAF gene signatures in H&E-stained images using additive multiple instance learning;2024-08-15

4. Changes in the tumour microenvironment mark the transition from serous borderline tumour to low‐grade serous carcinoma;The Journal of Pathology;2024-07-31

5. New insights into healthy ageing, inflammageing and frailty using metabolomics;Frontiers in Aging;2024-07-09